Autophagy-related chemoradiotherapy sensitivity in non-small cell lung cancer (NSCLC)

Firoozeh Abolhasani Zadeh; Ahmed Raji; Sana Abdul-Jabbar Ali; Walid Kamal Abdelbasset; Natalia Alekhina; A Heri Iswanto; Ermias Mergia Terefe; Abduladheem Turki Jalil

doi:10.1016/j.prp.2022.153823

Autophagy-related chemoradiotherapy sensitivity in non-small cell lung cancer (NSCLC)

Pathol Res Pract. 2022 May:233:153823. doi: 10.1016/j.prp.2022.153823. Epub 2022 Feb 24.

Authors

Firoozeh Abolhasani Zadeh¹, Ahmed Raji², Sana Abdul-Jabbar Ali³, Walid Kamal Abdelbasset⁴, Natalia Alekhina⁵, A Heri Iswanto⁶, Ermias Mergia Terefe⁷, Abduladheem Turki Jalil⁸

Affiliations

¹ Department of Surgery, Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran.
² College of medicine, University of Babylon, Department of Pathology, Babylon, Iraq.
³ Pharmacy department, Al-Safwa University, Karbalaa, Iraq. Electronic address: [email protected].
⁴ Department of Health and Rehabilitation Sciences, College of Applied Medical Sciences, Prince Sattam bin Abdulaziz University, Al Kharj, Saudi Arabia; Department of Physical Therapy, Kasr Al-Aini Hospital, Cairo University, Giza, Egypt.
⁵ PhD of Economics, Associate Professor at the Department of Regulatory Affairs in the Sphere of Drugs Products and Medical Devices, Sechenov First Moscow State Medical University, Moscow, Russia.
⁶ Public Health Department, Faculty of Health Science, University of Pembangunan Nasional Veteran, Jakarta, Indonesia.
⁷ School of pharmacy and Health science, United States International University, Nairobi, Kenya.
⁸ Faculty of Biology and Ecology, Yanka Kupala State University of Grodno, 230023 Grodno, Belarus; College of Technical Engineering, The Islamic University, Najaf, Iraq.

PMID: 35398616
DOI: 10.1016/j.prp.2022.153823

Abstract

Lung cancer is one of the leading causes of tumor-related mortalities worldwide. NSCLC is the most common type of lung cancer. In recent years, advancements in chemoradiotherapy and immunotherapy have led to unprecedented survival benefits in some patients. However, conventional therapies such as radiation and chemotherapy are not effective in all patients due to the chemo or radioresistance mechanisms; as a result, there is an urgent need for understanding the resistant mechanism. Given that malignancies are caused by changes in cell homeostasis, autophagy may help chemo/radiosensitization by removing damaged compartments and enhancing tumor clearance. Autophagy, on the other hand, may help cancer cells survive by increasing the breakdown of cell cycle regulators. Considering these inconsistencies, this study aimed to overview the intricacy of autophagy in response to chemoradiotherapy in lung cancer.

Keywords: Autophagy; Chemotherapy; Lung cancer; NSCLC; Raditherapy.

Publication types

Review

MeSH terms

Autophagy
Carcinoma, Non-Small-Cell Lung* / therapy
Chemoradiotherapy
Humans
Immunotherapy
Lung Neoplasms* / therapy